This is a Phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using
2 cohorts. The objective of the study is to evaluate the pharmacodynamics (PD) effects and
the pharmacokinetic (PK) of single day dosing of 2 mg and 4 mg doses of ertugliflozin (Ertu,
PF-04971729/MK-8835) each administered once vs twice daily (morning [AM] and evening [PM]) in
adults with type 2 diabetes.